Chemisys Laboratories, LLC

Chemisys Laboratories, LLC was paid $10.48M by Medicaid between Jan 2018 and Dec 2024, across 117 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 46% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#30 of 122

Median peer was paid$1.29M

This provider vs. median8.2×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	4,132	$205K
2019	14,404	$311K
2020	54,485	$843K
2021	90,681	$1.46M
2022	129,320	$2.12M
2023	191,975	$3.04M
2024incomplete	111,780	$2.50M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	46%	107,505	41,432	$4.82M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	25%	118,472	44,286	$2.62M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	11%	22,938	14,570	$1.15M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	10%	27,322	15,912	$1.06M
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	1.7%	9,053	6,669	$174K
82570		1.3%	72,707	21,115	$140K
83986		<1%	70,050	19,676	$96K
80050	General health panel	<1%	6,323	5,607	$48K
86769		<1%	1,979	1,812	$35K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,892	1,618	$34K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	7,620	6,401	$30K
80061	Lipid panel	<1%	7,942	6,967	$18K

105 more codes

86803		<1%	3,941	$15K
83036	Hemoglobin; glycosylated (A1C)	<1%	8,446	$14K
86704		<1%	3,383	$12K
87390		<1%	2,667	$11K
84443	Thyroid stimulating hormone (TSH)	<1%	3,972	$11K
87340		<1%	3,513	$11K
82607		<1%	3,393	$9K
86708		<1%	3,249	$9K
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	1,514	$9K
86702		<1%	2,668	$8K
84481		<1%	3,632	$8K
86706		<1%	2,957	$8K
87350		<1%	2,596	$7K
86701		<1%	2,674	$7K
82746		<1%	2,848	$6K
86707		<1%	2,593	$6K
80376		<1%	3,129	$5K
84439		<1%	4,279	$5K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	690	$5K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	4,248	$4K
80053	Comprehensive metabolic panel	<1%	4,028	$4K
82043		<1%	2,697	$4K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	484	$4K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	483	$4K
82728		<1%	3,062	$4K
86038		<1%	2,742	$3K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	80	$3K
84403		<1%	1,230	$3K
84153		<1%	1,611	$3K
82670		<1%	1,467	$3K
87391		<1%	713	$2K
83735		<1%	4,302	$2K
82378		<1%	2,511	$2K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	306	$2K
86301		<1%	2,545	$2K
81001		<1%	4,133	$2K
36415	Collection of venous blood by venipuncture	<1%	8,493	$2K
86592		<1%	3,174	$2K
83540		<1%	3,072	$2K
84480		<1%	1,751	$2K
83550		<1%	2,973	$2K
87086	Culture, bacterial; quantitative colony count, urine	<1%	717	$1K
80048	Basic metabolic panel (calcium, ionized)	<1%	418	$1K
86431		<1%	2,682	$1K
84550		<1%	3,445	$1K
80377		<1%	262	$1K
84100		<1%	3,629	$1K
84702		<1%	718	$1K
84436		<1%	2,134	$845.68
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	<1%	24	$817.35
85652		<1%	3,172	$756.06
83690		<1%	1,481	$741.20
83001		<1%	230	$568.14
87486		<1%	97	$552.56
87581		<1%	97	$512.79
86696		<1%	111	$497.83
83970		<1%	130	$491.68
80076		<1%	116	$472.37
86140		<1%	595	$467.01
84146		<1%	121	$455.32
84466		<1%	67	$400.60
85610		<1%	436	$342.19
83698		<1%	55	$337.77
83090		<1%	119	$331.92
82150		<1%	622	$322.30
85730		<1%	334	$318.18
84402		<1%	63	$285.06
86376		<1%	340	$284.59
84144		<1%	122	$283.21
86695		<1%	112	$272.61
83002		<1%	114	$265.45
87070		<1%	43	$220.80
86141		<1%	88	$218.47
82542		<1%	58	$197.60
84479		<1%	268	$192.58
86021		<1%	53	$164.67
82565		<1%	44	$145.89
83525		<1%	81	$136.68
83695		<1%	58	$128.88
86337		<1%	58	$93.69
85384		<1%	59	$93.06
82977		<1%	92	$55.31
81025		<1%	14	$51.09
84132		<1%	14	$49.82
86705		<1%	34	$41.34
84156		<1%	38	$29.53
87088		<1%	31	$23.10
82533		<1%	33	$17.00
85045		<1%	19	$3.76
82172		0%	177	$0.00
84305		0%	15	$0.00
81401		0%	49	$0.00
81291		0%	49	$0.00
81241		0%	49	$0.00
81355		0%	49	$0.00
81328		0%	49	$0.00
84681		0%	12	$0.00
82627		0%	16	$0.00
81226		0%	75	$0.00
81227		0%	74	$0.00
80352		0%	255	$0.00
81240		0%	49	$0.00
81230		0%	62	$0.00
81225		0%	62	$0.00
81231		0%	35	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKAMEL, AHMED (PRESIDENT)